Abstract 136P
Background
Recent studies indicated that Helicobacter pylori (H. pylori) exerts an oncogenic effect on the development of gastric diffuse large B-cell lymphoma (DLBCL). However, the effect of H. pylori status on prognosis of gastric DLBCL remains unconfirmed.
Methods
In the present study, H. pylori status was assessed by histologic examinations, supplemented by results from urease breath test and/or serological analyses where available. Staging tumours included a detailed medical history, physical examination which included peripheral lymph nodes and Waldeyer’s ring, complete hematological biochemical examinations containing serum lactate dehydrogenase (LDH), computed tomography (CT), gastric endoscopy, endoscopic ultrasonography, positron emission tomography (PET)/CT, and bone marrow aspiration and biopsy. Survival curves were estimated by Kaplan-Meier univariate analyses. The prognostic value of H. pylori was verified by both univariate and multivariate analyses.
Results
One hundred and twenty-nine patients diagnosed with primary de novo gastric DLBCL in West China Hospital of Sichuan University were included from 1st January 2009 to 31st May 2016. Over a median follow-up of 45.0 months (range 2-107), mean event-free survival (EFS) was 83.1 months (95% CI 72.7-93.5) and mean overall survival (OS) was 89.9 months (95% CI 80.9-98.9) in patients infected with H. pylori, compared with 62.0 months (95% CI 50.7–73.3) and 72.2 months (95% CI 61.6–82.9), respectively, in H. pylori-negative subgroup (P = 0.010 and P = 0.020 for differences in EFS and OS between groups, respectively). Patients with H. pylori infection had significantly better 5-year EFS and OS than H. pylori-negative subgroup (5-year EFS, 71% vs 47%, P = 0.010; 5-year OS, 79% vs 58%, P = 0.020). Older age, advanced Lugano stage, higher IPI score, and negative H. pylori status were independent negative prognostic indicators of survival outcomes.
Conclusions
H. pylori status in de novo gastric DLBCL can be a promising predictor of disease outcomes, and patients with negative H. pylori status should be followed up carefully since they tend to have a poor outlook.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract